Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by ESHRE Capri Workshop Group,
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by ESHRE Capri Workshop Group,
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Human Reproduction Update, Vol.9, No.3 pp.263-274, 2003
© European Society of Human Reproduction and Embryology 2003; all rights reserved

Mono-ovulatory cycles: a key goal in profertility programmes

ESHRE Capri Workshop Group1

1 A meeting was organized by ESHRE (Capri, September 1–2, 2002) with financial support from Ferring Pharmaceuticals to discuss the above subjects. The speakers included D.T.Baird (Edinburgh), J.Collins (Hamilton), P.G.Crosignani (Milano), J.L.H.Evers (Maastricht), R.Fanchin (Clamart), B.C.Fauser (Rotterdam), M.Filicori (Bologna), H.Jacobs (London), B.Tarlatzis (Thessaloniki). The discussants included: J.Cohen (Paris), E.Diczfalusy (Rönninge), K.Diedrich (Lubeck), L.Fraser (London), G.C.Frigerio (Milano), L.Gianaroli (Bologna), J.Harlin (Stockholm), J.Persson (Copenhagen), A.Rojas-Rìos (Copenhagen), A.Sunde (Trondheim), A.Van Steirteghem (Bruxelles). The report was prepared by J.Collins (Hamilton) and P.G.Crosignani2 (Milano).

To whom correspondence should be addressed at: 2P.G.Crosignani, e-mail: piergiorgio.crosignani{at}unimi.it

Abstract

Mono-ovulatory cycles for women are optimal because singleton pregnancies have a better outcome than multiples. Multiple births began to increase in the 1950s after the first appearance of effective ovulation induction for the treatment of anovulation. Since the 1980s when ovulation induction and IVF were more broadly applied to the treatment of unexplained and persistent infertility, there has been an unprecedented rise in multiple births. Strategies to achieve mono-ovulation during treatment of anovulatory patients are distinct from those for the treatment of ovulating patients who have unexplained and persistent infertility. Anovulatory patients with hypogonadotrophic hypogonadism can be treated with exogenous pulsatile GnRH, which restores normal gonadotrophin secretion, ovulation rates and conception rates. The multiple pregnancy rate is not increased with GnRH treatment. In patients with normogonadotrophic anovulation, attention should be given to diet and exercise before any other interventions are considered. Pharmacological induction of ovulation can be achieved with antiestrogen, gonadotrophin or pulsatile GnRH treatment; antiestrogen is the first choice with gonadotrophin more widely used for clomiphene citrate (CC)-resistant patients. Obesity and polycystic ovaries are common in this group, so that gonadotrophin and GnRH treatment are associated with lower responses compared with hypogonadotrophic hypogonadism, and higher multiple pregnancy rates. Low dosage protocols are being tested that may lower the multiple birth rates. The role of drugs enhancing sensitivity to insulin, e.g. metformin, remains undetermined. Laparoscopic ovarian diathermy achieves conception rates that are equivalent to gonadotrophin treatment, with fewer multiple births. Augmenting normal ovulation processes for couples with unexplained and persistent infertility is less effective. Pregnancy rates are statistically significantly higher with CC but the size of the increase is not clinically important. CC with intrauterine insemination is associated with a clinically important effect on conception. Achieving mono-ovulation is more difficult in assisted reproductive technology cycles because success depends on maintaining the level of FSH above the threshold level longer than normal in order to increase the number of mature follicles. Milder stimulation for IVF and IVF in the untreated cycle show great potential, however, especially in view of the trend toward transfer of a single embryo in assisted reproductive treatment cycles.

Key words:


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Hum ReprodHome page
The Thessaloniki ESHRE/ASRM-Sponsored PCOS Consens
Consensus on infertility treatment related to polycystic ovary syndrome
Hum. Reprod., March 1, 2008; 23(3): 462 - 477.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
R. S. Legro
A 27-Year-Old Woman With a Diagnosis of Polycystic Ovary Syndrome
JAMA, February 7, 2007; 297(5): 509 - 519.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
W. Ombelet, G. Martens, P. De Sutter, J. Gerris, E. Bosmans, G. Ruyssinck, P. Defoort, G. Molenberghs, and W. Gyselaers
Perinatal outcome of 12 021 singleton and 3108 twin births after non-IVF-assisted reproduction: a cohort study
Hum. Reprod., April 1, 2006; 21(4): 1025 - 1032.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
S. Palomba, A. Falbo, F. Orio Jr, F. Manguso, T. Russo, A. Tolino, C. Annamaria, B. Dale, and F. Zullo
A randomized controlled trial evaluating metformin pre-treatment and co-administration in non-obese insulin-resistant women with polycystic ovary syndrome treated with controlled ovarian stimulation plus timed intercourse or intrauterine insemination
Hum. Reprod., October 1, 2005; 20(10): 2879 - 2886.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
S. Palomba, F. Orio Jr., A. Falbo, F. Manguso, T. Russo, T. Cascella, A. Tolino, E. Carmina, A. Colao, and F. Zullo
Prospective Parallel Randomized, Double-Blind, Double-Dummy Controlled Clinical Trial Comparing Clomiphene Citrate and Metformin as the First-Line Treatment for Ovulation Induction in Nonobese Anovulatory Women with Polycystic Ovary Syndrome
J. Clin. Endocrinol. Metab., July 1, 2005; 90(7): 4068 - 4074.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
A. K. Omland, T. Abyholm, P. Fedorcsak, G. Ertzeid, N. B. Oldereid, S. Bjercke, and T. Tanbo
Pregnancy outcome after IVF and ICSI in unexplained, endometriosis-associated and tubal factor infertility
Hum. Reprod., March 1, 2005; 20(3): 722 - 727.
[Abstract] [Full Text] [PDF]


Home page
Hum Reprod UpdateHome page
W. Ombelet, P. De Sutter, J. Van der Elst, and G. Martens
Multiple gestation and infertility treatment: registration, reflection and reaction--the Belgian project
Hum. Reprod. Update, January 1, 2005; 11(1): 3 - 14.
[Abstract] [Full Text] [PDF]


Home page
Hum Reprod UpdateHome page
J. A. Collins and A. Van Steirteghem
Overall prognosis with current treatment of infertility
Hum. Reprod. Update, July 1, 2004; 10(4): 309 - 316.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
E.J.P. van Santbrink and B.C.J.M. Fauser
Is there a future for ovulation induction in the current era of assisted reproduction?
Hum. Reprod., December 1, 2003; 18(12): 2499 - 2502.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.